# Pumpkinseed Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pumpkinseed-bio

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.pumpkinseed.bio
- Total disclosed funding: $20M
- Latest round: Series A (May 5, 2026)
- Investors on record: 5

## About

Pumpkinseed Bio is a US-based biotech company specializing in protein analysis, utilizing advanced nanophotonic technology for precise protein sequencing and aiding in drug discovery and development.Pumpkinseed Bio focuses on innovative protein analysis through its proprietary DeSIPHR technology. Founded in Palo Alto, US in 2021, the company has successfully raised USD 20.00 mn in Series A funding on May 5, 2026, with participation from investors including Future Ventures, NFX, Adventures, Base4 Capital, and Stanford Investment Group. The firm operates independently and has not disclosed any pivots or subsidiary information. The founder's background is not specifically mentioned.Pumpkinseed is at the forefront of protein analysis through its proprietary product, DeSIPHR, which utilizes a nanophotonic chip platform for de novo protein sequencing. This technology allows for direct read-outs of protein identity, sequence, and modification state at single-molecule resolution, leveraging Raman spectroscopy with an unprecedented density of over 100 billion sensors per wafer. The main use cases for DeSIPHR revolve around enhancing drug discovery and development by accelerating target identification and mechanistic studies, as well as uncovering novel protein biomarkers and low-abundance signals that traditional methods often overlook. Pumpkinseed primarily serves biopharma companies, researchers, and academic institutions across key markets including North America, Europe, and parts of Asia, where there is a growing demand for high-resolution proteomic data.Pumpkinseed generates revenue through partnerships with biopharma firms, research institutions, and other entities involved in drug development and biological research. The company engages in B2B transactions, providing access to its DeSIPHR platform as a subscription service or through bespoke arrangements based on client needs. This revenue model includes licensing agreements, where clients pay for the usage of the technology in their proprietary research, alongside potential service fees for data analysis and interpretation. The nature of the offering suggests tiered pricing plans based on the scale of use and the complexity of the analysis required, particularly for flagship products such as DeSIPHR, which addresses critical challenges in the biopharma sector.In May 2026, Pumpkinseed Bio raised USD 20.00 mn in Series A funding, which the company will utilize to scale its protein sequencing platform and expand partnerships in biopharma and biosecurity. The funding will support the development of related data models. Specific plans for new products or geographic expansion have not been disclosed, but the emphasis will be on fostering growth and enhancing product offerings to better serve the biopharma market.

## Funding rounds

- Series A, May 5, 2026, $20M — Stanford Investment Group, NFX, Future Ventures, Adventures, Base4 Capital

## Investors

- Stanford Investment Group (https://capitalatlas.ai/funds/stanford-investment-group) — Series A
- NFX (https://capitalatlas.ai/funds/nfx) — Series A
- Future Ventures — Series A
- Adventures (https://capitalatlas.ai/funds/adventures) — Series A
- Base4 Capital (https://capitalatlas.ai/funds/base4-capital) — Series A